MétaCan
Menu
← Back to cohort

CD80 (B7.1) Is Expressed On Both Malignant B Cells and Tumor Infiltrating T Cells in Non-Hodgkin's Lymphomas.

2009· article· en· W2549537687 on OpenAlexaff
Shabnam Tangri, Naveen Dakappagari, Annalee Estrellado, Andrew P. Weng, Elizabeth A. Holmes, M. Wayne Saville, Kandasamy Hariharan, Steffan N. Ho

Bibliographic record

VenueBlood · 2009
Typearticle
Languageen
FieldMedicine
TopicCancer Immunotherapy and Biomarkers
Canadian institutionsBC Cancer Agency
Fundersnot available
KeywordsCD80Follicular lymphomaLymphomaCancer researchMantle cell lymphomaBiologyRituximabImmunologyImmune systemMedicineCytotoxic T cellCD40In vitro

Abstract

fetched live from OpenAlex

Abstract Abstract 1953 Poster Board I-976 CD80 is a member of the B7/CD28 family of regulatory proteins. B7/CD28 proteins are expressed on the surface of cells of the adaptive and innate immune system (i.e. lymphocytes, monocyte/macrophages, dendritic cells, myeloid-derived suppressor cells). These proteins function to establish a biologically optimal and dynamic balance between immune activation and inhibition or self-tolerance. Interactions between CD80 and its receptors, which include CD28, CTLA4 and PD-L1, contribute to both stimulatory as well as inhibitory or homeostatic regulation. Galiximab, an antibody directed against CD80, is currently under investigation for the treatment of follicular NHL. Initial clinical trials demonstrated that galiximab is well tolerated and suggest that combining galiximab with rituximab may provide clinical benefit. While expression of CD80 by malignant B cells in non-Hodgkin's lymphoma (NHL) has been reported, these studies utilized poorly quantitative immunohistochemical methods. To gain further understanding of the potential role of CD80 as a therapeutic target in NHL, CD80 expression was evaluated by six-color flow cytometric analysis of primary lymphoma cell suspensions generated from diagnostic biopsies of patients presenting with lymphadenopathy. Results obtained to date confirm that CD80 is uniformly expressed by malignant cells in a large majority of cases of follicular lymphoma (N=63), diffuse large B cell lymphoma (N=38), mantle cell lymphoma (n=7), marginal zone lymphoma (n=12) and small lymphocytic lymphoma (n=9). Furthermore, CD80 expression was also observed on tumor-infiltrating, non-malignant T cells. These results confirm the nearly ubiquitous expression of CD80 by malignant B cells in follicular, diffuse and other low grade NHL. Furthermore, these data demonstrate expression of CD80 by non-malignant cells (e.g. T cells) that define the tumor microenvironment. Further work to expand this dataset and to evaluate the expression of CD80 in non-T, non-B cells is ongoing. The expression of CD80 by malignant cells as well as non-malignant cells in NHL provides an opportunity to not only employ therapeutic antibodies to direct anti-tumor effector function such as antibody-dependent cellular cytotoxicity, but to also potentially interfere with interactions involving CD80 that might be involved in establishing an immune suppressive microenvironment supportive of tumor growth. Disclosures: No relevant conflicts of interest to declare.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.009
Threshold uncertainty score0.031

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0090.003

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.009
GPT teacher head0.235
Teacher spread0.227 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2009
Admission routes1
Has abstractyes

Explore more

Same venueBlood→Same topicCancer Immunotherapy and Biomarkers→French-language works237,207→